Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab

BACKGROUND: Pembrolizumab is an anti–programmed death 1 (PD-1) receptor monoclonal antibody that has shown activity as second line treatment for metastatic head and neck squamous cell carcinoma (HNSCC). Immune-related adverse events are now well described complications of PD-1 inhibitors and most or...

Descripción completa

Detalles Bibliográficos
Autores principales: Acero Brand, Fanny Zulay, Suter, Nicolas, Adam, Jean-Philippe, Faulques, Bernard, Maietta, Antonio, Soulières, Denis, Blais, Normand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857140/
https://www.ncbi.nlm.nih.gov/pubmed/29548299
http://dx.doi.org/10.1186/s40425-018-0332-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5857140/
https://www.ncbi.nlm.nih.gov/pubmed/29548299
http://dx.doi.org/10.1186/s40425-018-0332-z

Ejemplares similares